Navigation Links
Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
Date:5/30/2012

results may differ materially from those reflected in these forward-looking statements due to various factors, including further evaluation of clinical data, results of clinical trials, decisions by regulatory authorities as to whether and when to approve drug applications, and general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries and those discussed in Auxilium's Annual Report under the heading "Risk Factors" on Form 10-K for the year ended December 31, 2011, and Form 10-Q for the quarter ended March 31, 2012, which are on file with the Securities and Exchange Commission (the "SEC") and may be accessed electronically by means of the SEC's home page on the Internet at http://www.sec.gov or by means of Auxilium's home page on the Internet at http://www.Auxilium.com under the heading "For Investors -- SEC Filings." There may be additional risks that Auxilium does not presently know or that Auxilium currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements.

In addition, forward-looking statements provide Auxilium's expectations, plans or forecasts of future events and views as of the date of this release. Auxilium anticipates that subsequent events and developments will cause Auxilium's assessments to change. However, while Auxilium may elect to update these forward-looking statements at some point in the future, Auxilium specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Auxilium's assessments as of any date subsequent to the date of this release.For More Information, Contact:James E. F
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Results and Conduct Conference Call on Thursday, February 10, 2011
2. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011
3. Auxilium Pharmaceuticals to Announce First Quarter 2011 Results and Conduct Conference Call on Monday, May 9, 2011
4. Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights
5. Auxilium Pharmaceuticals, Inc. Updates Launch Progress of XIAPEX® in EU
6. Auxilium Pharmaceuticals to Present at the Morgan Stanley 2011 Healthcare Conference
7. Auxilium Pharmaceuticals, Inc. Announces 17 Month XIAFLEX® Safety Update
8. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2011 Financial Results and Recent Operational Highlights
9. Auxilium Announces Appointments to Enhance Leadership Team
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
11. VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... November 23, 2014 One of the most ... optics and photonics is now available to high school and ... cost. SPIE, the international society for optics and photonics ... complete SPIE Digital Library available to high schools ... “Light-based technologies are integral to all areas of life in ...
(Date:11/24/2014)... 24, 2014 Senior Vice President, ... dynamic leadership skills, business acumen Elsevier ... information products and services, congratulates Diane Bartoli , ... and Workflow, Elsevier Clinical Solutions, for being recognized in ... Awards issue of Profiles in Diversity Journal ...
(Date:11/22/2014)... CannLabs, Inc. (OTCQB: CANL), the leading ... methodologies relating to cannabis, today announced that it has ... from an existing stockholder of the Company. , ... from one of our existing stockholders,” stated Mark ... help accelerate our planned expansions into the Connecticut and ...
(Date:11/22/2014)... element of surprise has been a major advantage of ... Until now, epidemiologists had nothing to measure that might ... suboptimal responses to both the H1N1 pandemic of 2009 ... http://photos.prnewswire.com/prnh/20141121/160242 That virus advantage ... structural changes have been found that invariably to date ...
Breaking Biology Technology:SPIE Digital Library Now Available to High Schools, Two-Year Colleges at No or Low Cost 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 3CannLabs Secures $750,000 Line Of Credit 2Viruses' Advantage of Surprise is Lost 2
... Accelerates Expected Timing of Final Analysis by One, Year While Maintaining ... on Thursday, March 13, 2008 at 11:00 AM ... ... Corporation,(Nasdaq: DNDN ) today announced that the U.S. Food and Drug ...
... Collaboration with Amgen- ... at 9:00 A.M. EDT-, MONTVALE, N.J., March 12 ... that it has realigned,its operations, reallocated its resources and ... Amgen. The Company will,focus its near-term and mid- term ...
... Research Ltd., a global,contract research and development organization, today ... President., Mr. Cline comes to Cato Research from ... served as President and CEO. Mr. Cline has over ... marketing roles at Organon Inc., Caremark, a division of ...
Cached Biology Technology:FDA Agrees to Amend Dendreon's Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE 2FDA Agrees to Amend Dendreon's Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE 3FDA Agrees to Amend Dendreon's Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE 4Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs 2Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs 3Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs 4Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs 5Cato Research Names John Cline as President 2
(Date:11/4/2014)... – Temple University School of Medicine announced today ... an initiative funded by the Bill & Melinda ... of Obstetrics, Gynecology and Reproductive Sciences; and Vice ... University School of Medicine will pursue an innovative ... Blood Biomarkers to Assess Fetal Neurodevelopment.", Grand Challenges ...
(Date:11/4/2014)... – (Nov. 4, 2014) – A majority of Madagascar,s ... that could have serious consequences for the rainforests they ... shows the positive impacts lemurs can have on rainforest ... their disappearance could have on the region,s rich biodiversity. ... have fruits eaten by lemurs. Lemurs in turn ...
(Date:11/3/2014)... LOS ANGELES , Nov. 3, 2014 /PRNewswire/ ... California -based life sciences company focused on ... eTNS system for the treatment of neurological ... Institute of Industrial Property has issued a Notice ... The patent application is co-owned by NeuroSigma and ...
Breaking Biology News(10 mins):Temple University School of Medicine receives Grand Challenges Explorations grant 2Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... News headlines are filled with discussion and ... Change Conference in Copenhagen. As expected, the ... has focused on traditional environmental measures - regulations ... sources, etc. A new book Paradise Regained: ...
... PHILADELPHIA People with the heritable disorder of ... to develop basal cell carcinoma of the skin may ... According to results of a placebo-controlled, randomized, double-blind, ... in inhibiting the development of basal cell carcinomas in ...
... plan to put two and two together in a study ... Two traits that impact corn will be examined by ... products at the farm level. Drought tolerance and aflatoxin ... Research scientists who have been awarded a $500,000 grant for ...
Cached Biology News:Global warming and other environmental dangers may be solved by unlikely source -- space technology 2Celebrex inhibited the burden of skin cancer in high-risk patients 2Genes for drought-tolerance, aflatoxin may mingle to boost corn production 2
... Life Science FLA-7000 excels at fluorescent and ... documentation. It features four easy-to-access filters (filters ... filter for Imaging Plates) for upgrading flexibility. ... choice of four kinds of excitation laser ...
... ULS cDNA Synthesis and Labeling Kit generates ... experiments. First unmodified cDNA is made via ... using an Oligo(dT) primer. Unlike other methods, ... in the reverse transcription reaction. This unmodified ...
... fully automated hybridization of microarrays on slides. ... designed to offer researchers improved reproducibility, superior ... a wide range of applications. Incubations ... denaturations of up to 99C. The possibility ...
... user-friendly Eppendorf Thermomixer R offers maximum ... require shaking, heating, and cooling. Its ... its application and temperature control ranges. ... accommodate 24 micro test tubes, are ...
Biology Products: